Pulse Biosciences Inc

Long-term bullish structure remains intact, but the active Bullish Exhaustion pattern and extreme overbought readings following a parabolic advance indicate waning upside momentum. Price is rejecting overhead resistance and extended above short-term EMAs, creating medium-term asymmetry that favors a corrective pullback. Short-term price action confirms immediate sell execution in the resistance zone.

• ↑Q4’25 revenue $264K vs. $86K in Q3’25, evidencing early commercialization traction
• ↑Feasibility studies report 100% procedural success, underscoring nsPFA’s clinical efficacy
• ↓Q4 2025 GAAP net loss $19.4M; R&D and trial costs pressure margins